Dacomitinib

Dacomitinib is an orally bioavailable, selective second-generation small molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antitumor activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR isoforms, thereby inhibiting proliferation and inducing apoptosis in EGFR-expressing tumor cells.

• Supplier: Alfa Cytology
• Product #: BC0392